Purpose of the Study

The purpose of this study is to evaluate the safety, tolerability, and effectiveness of an investigational medication in individuals with APOL1-dependent FSGS. The word “investigational” means this medication is not yet approved for use by the Food and Drug Administration (FDA) in the United States or other regulatory agencies in the UK, Europe, or elsewhere.

Who May Qualify

Eligible participants must meet the following criteria:

• Be male or female between the ages of 18 and 60 (inclusive)
  • Female participants must not be pregnant or nursing
• Have had a diagnosis of focal segmental glomerulosclerosis via a kidney biopsy
• Have a high-risk apolipoprotein L1 (APOL1) genotype
• Have not had a diagnosis of kidney disease other than FSGS
• Be willing and able to comply with the study instructions

There are additional eligibility requirements, which the study doctor can explain to you.

Study Participation

We are looking for adults between the ages of 18 and 60 with a high-risk APOL1 gene variation and biopsy-confirmed FSGS to participate in this clinical research study. Testing for the APOL1 gene is included in this clinical study.

Interested individuals will be evaluated during a screening period to determine their eligibility to participate. Your participation could last approximately 17 weeks followed by an optional off-treatment observation period lasting up to 12 weeks. You and your study doctor may choose to have some of the study visits at your home with a home health nurse followed by a telemedicine video visit or phone call with the study doctor, allowing for a reduced number of times that you must travel to the study site.

See if you may qualify

For Families and Caregivers

If your loved one is living with FSGS, share this website with them today, or talk to their doctor for more information.